

<b>Affiliation</b>	<b>Medical Director/Investigator</b> Clinical Neuroscience Solutions, Inc. 618 East South Street, Suite 100 Orlando, FL 32801 01/00 – present	<b>Investigator</b> Clinical Neuroscience Solutions, Inc. 2863 S. Delaney Avenue Orlando, FL 32806 07/16 - Present
<b>License/Accreditation</b>	Florida Medical License Number: ME 47298  Board Eligible, American Board of Psychiatry and Neurology	
<b>Good Clinical Practices</b>	CNS Healthcare: “Standard Operating Procedures including GCP”, 2017  National Institutes of Health (NIH): “Protecting Human Research Participants”, 04/20/15  Other sponsor required GCP	
<b>Professional Organizations</b>	Society for Clinical Research Sites (SCRS)	
<b>Clinical Trial Experience and Interests</b>	Investigator on over 390 phase I-IV clinical trials in pediatric, adolescents, adults and geriatrics.  Diagnoses include: Acne, Alzheimer’s, Asthma, Attention-deficit/hyperactivity disorder, Autism, Binge eating, Bipolar disorder, Alcohol dependency, Chronic idiopathic constipation, Chronic low back pain, Depressive disorders, Dementias, Diabetes Type I and Type II, Diabetic peripheral neuropathy, Chronic fatigue, Female sexual arousal disorder, Fibromyalgia, Flu treatment, Flu vaccine, Generalized anxiety disorder, Hot flashes, Hyperlipidemia, Hypertension, Hypoactive sexual desire disorder, Influenza, Insomnia, Irritable bowel syndrome, Lower back pain, Menstrual Migraine, Migraine prevention, Mild cognitive impairment, Obsessive-compulsive disorder, Opioid induced constipation, Opioid withdrawal, Osteoarthritis pain of the knee, Panic disorder, Post-herpetic neuralgia, Post-traumatic stress disorder, Schizoaffective disorder, Schizophrenia, Sexual dysfunction, Smoking cessation, Social phobia and Stuttering.	
<b>Industry Contacts</b>	Abbott Laboratories, Actavis, Addrenex, Alcobra, Alder, Alkermes, Allergan, Allon, Amgen, Arbor, Arena, AstraZeneca, AssureRx, Avanir, Axsome, BioDelivery, Biogen, Biovail Laboratories, Boehringer-Ingelheim, Braintree, Bristol-Myers Squibb, Celltech, CeNeRx, Cephalon, Cerecor, Collegium, Colucid, Covidien, Cubist, Daiichi, Depomed, DOV, Dr. Reddy’s Laboratories, Edgemont, Eisai, Eli Lilly, Elcelyx, Endo Pharmaceuticals, Esperion, Euthymics, Forest, Furiex, Genomind, GlaxoSmithKline, Grunenthal, Indevus/Endo, Ironshore, Janssen, Jazz, Johnson & Johnson, Labopharm, Labrys, Lundbeck, Medgenics, Merck, Mitsubishi, MSI	

Methylation Sciences, Myriad, Neuralstem, Neurosearch, Nestle/PamLab, New River Pharmaceuticals, Novan, Novartis, Noven, NovoNordisk, ONO, Organon, Ortho-McNeil, Otsuka, Palatin Technologies, Pfizer, PGxHealth, Purdue, Regeneron, Repligen, Roche, Saegis, Sanofi, Sepracor, Shionogi, Shire, SmithKline Beecham, Solvay, Supernus, Synergy, Synosia, Takeda, Targacept, TEVA, Tonix, Transtech, US WorldMeds, Vanda, Vertex and Wyeth.

**Professional Experience**

Private Practice in Psychiatry, Orlando, Florida and Kissimmee, FL;  
1987 – 2004

Psychiatrist, Consultation Services, Orlando Regional Medical Center, Orlando and Longwood, FL;  
1988 – 2005

Psychiatrist, Consultation Services, Florida Hospital, Orlando, FL;  
1989 – 2001

Psychiatric Medical Director, Charter Health System, Clinical Trials Program, Kissimmee, FL;  
1997 – 1999

Director of Addictions Unit, Florida Hospital, Orlando, FL;  
1987 – 1988

Staff Physician, Emergency Medicine, Emergency Room; Multiple Hospitals, GA and FL;  
1984 – 1986

**Professional Training**

Resident, University of South Florida College of Medicine, Geriatric Fellowship, Tampa, FL;  
1986 – 1987

Intern and Resident, Medical College of Georgia, Department of Psychiatry, Augusta, GA;  
1982 – 1984; 1985 – 1986

Intern, Memorial Medical Center, Department of Internal Medicine, Savannah, GA;  
1984 – 1985

**Education**

CEBU Doctor's College of Medicine  
Doctor of Medicine;  
1978 – 1982

University of Central Florida, Orlando, Florida  
Bachelor of Arts in Psychology and Bachelor of Science in Biology;  
1972 – 1976

**Publications/Reviews/  
Book Chapters**

Fava, M., Mischoulon, D., Iosifescu, D., Witte, J., Pencina, M., Flynn, M., Harper, L., Levy, M., Rickels, K., & Pollack, M. (2009). A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy (ADT) among depressed outpatients with inadequate response to prior ADT (ADAPT-A Study).

Childress, A., Muniz, R., Harper, L., Miller, J., Arnold, V., Gerstner, O., Borello, M., Thulasiramin, A., & Post, A. A fixed-dose titration study of desmethylphenidate extended release in children with ADHD. AACAP.

Harper, L., Schmechel, D., Gerard, G., Vatakis, N., Ross, J.S., Bari, M., Walling, D., Stedman, M., Winston, J., Morimoto, B., & Keith, J. (2008). A phase 2, double-blind, placebo-controlled study to evaluate the safety, tolerability and effect on cognitive function of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment.

**Professional Poster  
Presentations**

Brown, P.W., Hummel, R., Molpus, R.B., Joyce, M., Harper, L., Wood, T., Menosky, A. & Ehrhardt, J. (2014). Complex protocol design ≠ better trial outcomes. Presented from New Clinical Drug Evaluation Unit (NCDEU) Meeting, Hollywood, FL.

Brown, P.W., Joyce, M., Molpus, R.B., Harper, L.S., Wood, T., Hummel, R. & Menosky, A. (2013). Failed trials and protocol design: Is there a relationship? Presented from New Clinical Drug Evaluation Unit (NCDEU) Meeting, Phoenix, AZ.

Hunter, B.D., Brown, P.W., Angel, S., Carmichael, L., Harper, L.S., Joyce, J.M., & McGill, L.J. (June 2012). The impact of patient recruitment methods on data quality. Presented from New Clinical Drug Evaluation Unit (NCDEU) Meeting, Phoenix, AZ.